학술논문

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
Document Type
Academic Journal
Source
Molecular and Clinical Oncology. August 2022, Vol. 17 Issue 2
Subject
Libya
Language
English
ISSN
2049-9450
Abstract
Introduction Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and the fourth leading cause of cancer-related mortality (1). Despite advances in diagnostic and therapeutic strategies over the [...]
The present study investigated the associations of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels with clinicopathological variables and survival outcomes in Libyan patients with pancreatic ductal adenocarcinoma (PDAC). The clinicopathological variables of 123 patients with PDAC registered at the National Cancer Institute in Misurata, Libya, between 2010 and 2018 were retrospectively analyzed. Blood samples from these patients were analyzed for serum CEA and CA19-9 levels before treatment by electrochemiluminescence immunoassay (double antibody sandwich ELISA) on a Roche cobas e 602 modules. The relationships between CA19-9 and CEA serum levels with clinicopathologic variables and survival outcomes were analyzed using the Kaplan-Meier method, log-rank test and Cox regression analyzes. Cut-off values for serum CEA and CA19-9 levels were 5 ng/ml and 400 U/ml, respectively. The median serum levels of all patients with PDAC for CEA and CA19-9 were 8 ng/ml (1.1-377 ng/ml) and 389 U/ml (1-10,050 U/ml), respectively. Tumors with higher serum CEA and CA19-9 levels were found in 63 and 48% of patients, respectively. Higher CEA and CA19-9 serum levels were significantly associated with more indicators of a malignant phenotype, including a surgically unresectable tumor, unevaluable lymph nodes, advanced stages and distant metastases. Regarding survival, patients with higher serum levels of the biomarkers CEA and CA19-9 had shorter overall survival rates (P Key words: pancreatic ductal adenocarcinoma, carcinoembryonic antigen, carbohydrate antigen 19-9, ELISA, expressions, prognosis, survival outcomes